AMG 557

DRUG4 trials

Sponsors

Amgen

Conditions

Cutaneous LupusLupusLupus Arthritis, Systemic Lupus ErythematosusSystemic Lupus Erythematosus

Phase 1

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

CompletedNCT00774943

AmgenSystemic Lupus Erythematosus

Start: 2008-12-31End: 2012-05-31Updated: 2013-04-09

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

TerminatedNCT01389895

AmgenCutaneous Lupus, Lupus

Start: 2011-10-31End: 2013-03-31Updated: 2014-01-10

Safety Study of AMG 557 in Subjects With Lupus Arthritis

CompletedNCT01683695

AmgenLupus Arthritis, Systemic Lupus Erythematosus

Start: 2012-06-30End: 2016-03-31Updated: 2017-01-24

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

CompletedNCT02391259

AmgenSystemic Lupus Erythematosus

Start: 2006-11-30End: 2011-11-30Updated: 2015-03-30

Related Papers

Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus

Lupus Science & Medicine2016-04-0171 citations